These types of improvements are relatively common after initial approval and are the result of optimization as surgical techniques and knowledge evolve.
Researchers determined that the PDS may decrease the treatment burden of frequent intravitreal injections, but further research on efficacy and safety is needed.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.
“After the introduction of once-weekly semaglutide in Denmark in November 2018, the annual number of first-time NAION episodes reached an all-time high for the years 2019 through 2023.”